Table 1 Baseline demographic, clinical and immunological characteristics in the two groups
|  | D(HBsAg+)/R(HBsAg-) group (n = 83) | D(HBcAb+)/R(HBcAb-) group (n = 83) | P value |
|---|---|---|---|
Donor | |||
 Median age, year (range) | 50 (31–66) | 48 (28–66) | 0.133 |
 Male (%) | 39 (47.0) | 40 (48.2) | 1.000 |
 Living related (%) | 83 (100) | 83 (100) | / |
Recipient | |||
 Median age, year (range) | 32 (9–51) | 29 (15–51) | 0.093 |
 Male (%) | 64 (77.1) | 64 (77.1) | 1.000 |
 Cause of end stage renal failure | |||
  Glomerulonephritis (%) | 40 (48.2) | 26 (31.3) | 0.084 |
  Non-glomerulonephritis (%) | 8 (9.6) | 10 (12.0) |  |
  Unknown (%) | 35 (42.2) | 47 (56.6) |  |
 Preemptive transplant (%) | 6 (7.2) | 9 (10.8) | 0.588 |
 Median duration on dialysis, months (range) | 9 (0–120) | 8 (0–84) | 0.497 |
 Mean HLA mismatch (A, B, DR, DQ) | 4.04 ± 1.47 | 3.46 ± 1.07 | 0.004 |
 PRA > 0(%) | 27 (32.5) | 22 (26.5) | 0.496 |
 Second transplant | 0 | 0 | / |
 Induction therapy | |||
  IL-2 receptor antagonist (%) | 49 (59.0) | 55 (66.3) | 0.553 |
  Antithymocyte globulin (%) | 18 (21.7) | 13 (15.7) |  |
  No induction (%) | 16 (19.3) | 15 (18.1) |  |
 Initial immunosuppression | |||
  Tac + MPA + Pred (%) | 78 (94.0) | 80 (96.4) | 0.469 |
  CsA + MPA + Pred (%) | 5 (6.0) | 3 (3.6) |  |